Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.

摘要: Thrombotic adverse events (AEs) after clotting factor concentrate administration are rare but the actual rate is unknown. A systematic review of prospective studies (1990-2011) reporting safety data concentrates in patients with haemophilia (HA), B (HB) and von Willebrand disease (VWD) was conducted to identify incidence type thrombotic AEs. In 71 (45 HA, 15 HB, 11 VWD) enrolling 5528 treated 27 different (20 plasma-derived, 7 recombinant), 20 AEs (2 were reported, including two major venous thromboembolic episodes (both VWD on prolonged replacement for surgery). The remaining superficial thrombophlebitis, mostly occurring at infusion sites surgical and/or during continuous infusion. overall prevalence 3.6 per 10(3) (3.6 10(4) severe AEs) 1.13 10(5) infusions, higher figures than haemophilia. accounted 1.9% non-inhibitor-related Thrombosis-related complications occurred 10.8% central access devices (CVADs) reported six studies, risk increasing time CVAD use. Data from over last years suggest that small mainly represented by thrombophlebitis. These findings support high degree products currently used treatment.